Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560389 | 1.00 | RXRA (0.34) | RXRAGRIN1GRIN2BMETHTT | |
| SCHEMBL29217774 | 0.85 | MET (0.32) | METHTTKMT2A | |
| SCHEMBL26602992 | 0.83 | MET (0.38) | METHTTKMT2ANPC1RAB9A | |
| SCHEMBL31087498 | 0.83 | MET (0.38) | METHTTKMT2ANPC1RAB9A | |
| SCHEMBL22711852 | 0.82 | MET (0.39) | METACACB | |
| SCHEMBL30900386 | 0.81 | HTT (0.32) | HTTKMT2ANPC1RAB9ATRPV4 | |
| SCHEMBL16648664 | 0.81 | RXRA (0.34) | RXRAGRIN1GRIN2BMETHTT | |
| SCHEMBL16858570 | 0.79 | PLAU (0.39) | METHTTKMT2ANPC1RAB9A | |
| SCHEMBL15052308 | 0.79 | AAK1 (0.38) | RXRAGRIN1GRIN2BMETHTT | |
| SCHEMBL26956867 | 0.79 | HTT (0.39) | METHTTKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116134018-A | 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4168393-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-04-06 | — | — | US | disclosed |
| EP-3994139-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | Effector Therapeutics Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114269756-A | 4-oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds inhibiting EIF4E | 效应疗法股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EFFECTOR THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210403457-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021257490-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403457-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | RXRA 4294/4885GRIN1 298/4885GRIN2B 271/4885 |
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EIF4E, EIF4EBP1, EIF4A1 | RXRA 4117/4885GRIN1 2503/4885GRIN2B 3194/4885 |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | SCN8A, TRPV1, SCN2A | RXRA 4294/4885GRIN1 298/4885GRIN2B 271/4885 |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | EIF4E, EIF4EBP1, EIF4A1 | RXRA 4117/4885GRIN1 2503/4885GRIN2B 3194/4885 |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | RXRA 4161/4885GRIN1 311/4885GRIN2B 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.